Cargando…

Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia

INTRODUCTION: Ready-to-use glucagon represents a significant advancement in the management of severe hypoglycemia for people with diabetes and their caregivers. This indirect treatment comparison (ITC) evaluated the efficacy and safety differences among the three ready-to-use glucagon treatments, Ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giménez, Marga, Khunti, Kamlesh, Matsuhisa, Munehide, Chenji, Suresh, Syring, Kristen, Yan, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570215/ https://www.ncbi.nlm.nih.gov/pubmed/37707700 http://dx.doi.org/10.1007/s13300-023-01466-6

Ejemplares similares

New risk factors of severe hypoglycemia
por: Matsuhisa, Munehide, et al.
Publicado: (2018)

The current status of treatment‐related severe hypoglycemia in Japanese patients with diabetes mellitus: A report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society
por: Namba, Mitsuyoshi, et al.
Publicado: (2018)

Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain
por: Osumili, Beatrice, et al.
Publicado: (2022)

Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
por: Pontiroli, Antonio E., et al.
Publicado: (2022)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia, Nitil
Publicado: (2011)

Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States
por: Bajpai, Sanjay, et al.
Publicado: (2021)

A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia
por: Bailey, Naila Celeste, et al.
Publicado: (2022)

MON-LB115 Ready-To-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia in a Clinical Research Setting
por: Aronson, Ronnie, et al.
Publicado: (2020)

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies
por: Christiansen, Mark P, et al.
Publicado: (2021)

A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia()
por: Chabenne, Joseph, et al.
Publicado: (2014)

Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes
por: Aronson, Ronnie, et al.
Publicado: (2023)

Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia
por: Pontiroli, Antonio E., et al.
Publicado: (2019)

Nasal glucagon as a viable alternative for treating insulin‐induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study
por: Matsuhisa, Munehide, et al.
Publicado: (2020)

Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial
por: Battelino, Tadej, et al.
Publicado: (2021)

MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure
por: Pettus, Jeremy H, et al.
Publicado: (2020)

Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia
por: Bajpai, Sanjay K, et al.
Publicado: (2022)

The multinational Conversations and Reactions Around Severe Hypoglycemia (CRASH) study: Impact of health care provider communications and recommendations on people with diabetes
por: Snoek, Frank J., et al.
Publicado: (2022)

Comment on: Gruden et al. Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications Study. Diabetes Care 2012;35:1598–1604
por: Giménez, Marga, et al.
Publicado: (2012)

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study
por: Yale, Jean-François, et al.
Publicado: (2017)

Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes
por: Siafarikas, Aris, et al.
Publicado: (2012)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective
por: Harris, Stewart B, et al.
Publicado: (2013)

Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?
por: Porcellati, Francesca, et al.
Publicado: (2021)

Severe Hypoglycemia and the Use of Glucagon Rescue Agents: An Observational Survey in Adults With Type 1 Diabetes
por: Hughes, Allyson S., et al.
Publicado: (2023)

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
por: Rickels, Michael R., et al.
Publicado: (2016)

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
por: Potts, Jessica E., et al.
Publicado: (2015)

Mitochondrial GTP Insensitivity Contributes to Hypoglycemia in Hyperinsulinemia Hyperammonemia by Inhibiting Glucagon Release
por: Kibbey, Richard G., et al.
Publicado: (2014)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Why Glucagon Matters for Hypoglycemia and Physical Activity in Individuals With Type 1 Diabetes
por: Colberg, Sheri R.
Publicado: (2022)

Indirect impact of the COVID-19 pandemic on hospitalisations for cardiometabolic conditions and their management: A systematic review
por: Seidu, Samuel, et al.
Publicado: (2021)

Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study
por: Miyoshi, Hideaki, et al.
Publicado: (2023)

Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

A Case of Hypocalcemia with Severe Vitamin D Deficiency following Treatment for Graves' Disease with Methimazole
por: Miyashita, Kazuyuki, et al.
Publicado: (2013)

Puzzling About Partial Glucagon Responses to Hypoglycemia in Intrahepatic Islet Recipients: Missing Pieces
por: Robertson, R. Paul
Publicado: (2015)

Hypothalamic Irak4 is a genetically controlled regulator of hypoglycemia-induced glucagon secretion
por: Picard, Alexandre, et al.
Publicado: (2022)

Severe hypoglycemia in propranolol treatment for infantile hemangiomas
por: Morimoto, Akira, et al.
Publicado: (2022)

Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study
por: Tetzschner, Rikke, et al.
Publicado: (2019)

Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation
por: Valentine, Virginia, et al.
Publicado: (2019)

Repeated Episodes of Hypoglycemia as a Potential Aggravating Factor for Preclinical Atherosclerosis in Subjects With Type 1 Diabetes
por: Giménez, Marga, et al.
Publicado: (2011)

Comparison of continuous subcutaneous insulin infusion treatment and multiple daily injection treatment on the progression of diabetic complications in Japanese patients with juvenile‐onset type 1 diabetes mellitus
por: Masuda, Takafumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7265e05v4ei16h711920jiggc4